Developing a Batch Isolation Procedure and Running It in an Automated Semicontinuous Unit: AWL CFD25 Case Study.


Journal

Organic process research & development
ISSN: 1083-6160
Titre abrégé: Org Process Res Dev
Pays: United States
ID NLM: 9890443

Informations de publication

Date de publication:
17 Apr 2020
Historique:
received: 29 11 2019
entrez: 28 4 2020
pubmed: 28 4 2020
medline: 28 4 2020
Statut: ppublish

Résumé

A key challenge during the transition from laboratory/small batch to continuous manufacturing is the development of a process strategy that can easily be adopted for a larger batch/continuous process. Industrial practice is to develop the isolation strategy for a new drug/process in batch using the design of experiment (DoE) approach to determine the best isolation conditions and then transfer the isolation parameters selected to a large batch equipment/continuous isolation process. This stage requires a series of extra investigations to evaluate the effect of different equipment geometry or even the adaptation of the parameters selected to a different isolation mechanism (e.g., from dead end to cross flow filtration) with a consequent increase of R&D cost and time along with an increase in material consumption. The CFD25 is an isolation device used in the first instance to develop an isolation strategy in batch (optimization mode) using a screening DoE approach and to then verify the transferability of the strategy to a semicontinuous process (production mode). A d-optimal screening DoE was used to determine the effect of varying the input slurry. Properties such as solid loading, particle size distribution, and crystallization solvent were investigated to determine their impact on the filtration and washing performance and the characteristics of the dry isolated product. A series of crystallization (ethanol, isopropanol, and 3-methylbutan-1-ol) and wash solvents (

Identifiants

pubmed: 32336906
doi: 10.1021/acs.oprd.9b00512
pmc: PMC7171873
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

520-539

Informations de copyright

Copyright © 2020 American Chemical Society.

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Int J Pharm. 2004 Feb 11;270(1-2):263-77
pubmed: 14726141
J Pharm Sci. 2019 Jan;108(1):372-381
pubmed: 30009797

Auteurs

Sara Ottoboni (S)

EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.

Muhid Shahid (M)

EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.

Christopher Steven (C)

EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.
Alconbury Weston, Stoke-on-Trent ST4 3PE, U.K.

Simon Coleman (S)

EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.
Alconbury Weston, Stoke-on-Trent ST4 3PE, U.K.

Elisabeth Meehan (E)

Pharmaceutical Technology and Development, AstraZeneca, Macclesfield SK10 2NA, U.K.

Alastair Barton (A)

Alconbury Weston, Stoke-on-Trent ST4 3PE, U.K.

Paul Firth (P)

Alconbury Weston, Stoke-on-Trent ST4 3PE, U.K.

Richard Sutherland (R)

Alconbury Weston, Stoke-on-Trent ST4 3PE, U.K.

Chris J Price (CJ)

EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation, University of Strathclyde, Glasgow G1 1RD, U.K.
Department of Chemical and Process Engineering, University of Strathclyde, Glasgow G1 1RD, U.K.

Classifications MeSH